AngioDynamics to Launch VenaCure EVLT(TM), New Brand for Varicose Vein Treatment.

Superior Patient Experience, Proprietary Practice Builder & Top Training, All in One Solution

QUEENSBURY, N.Y. -- AngioDynamics Inc. (NASDAQ:ANGO) today announced it will launch a new varicose vein therapy brand, VenaCure EVLT, at the American College of Phlebology (ACP) 22nd Annual Congress, November 6th to 9th at the Marco Island Marriott Resort & Spa in Florida. The new brand will encompass the best of AngioDynamics' VenaCure([R]) product line as well as EVLT([R]), a product line which AngioDynamics recently rescued from the bankruptcy of Diomed Inc.

Participants at the ACP Congress will find the AngioDynamics booth directly across from the entrance to the exhibit hall in booths 101 through 107.

"As the name conveys, our new brand will be everything you liked about VenaCure and EVLT in one package," said Sean Morris, Senior Vice President/General Manager of AngioDynamics' Peripheral Vascular Division. "We have now combined the best of Diomed and AngioDynamics into a dream team offering for physicians and their patients. Patients get an effective, outpatient alternative to otherwise painful and invasive surgery. Physicians get continuous support from AngioDynamics to develop their clinical practices and provide patients with the best treatment available."

The new line will now be available through AngioDynamics' Peripheral Vascular Division as a comprehensive package of innovative, minimally invasive medical devices for practices involved in the treatment of superficial venous disease. This includes the Delta Diode laser, a complete offering of procedure kits with the proprietary NeverTouch([R]) laser fiber, and accessories including the only FDA approved, commercially available sodium tetradecyl sulfate injection on the U.S. market, Sotradecol([R]).

In addition, AngioDynamics will be the only laser treatment provider to offer both total patient marketing support with its Maximizing VenaCure Potential (MVP) program and complete physician training with its VenaCure in Practice (VIP) program. MVP provides easily accessible online resources to physicians and patients, spreading awareness of VenaCure EVLT to the roughly three million patients who seek out varicose vein information on the Internet each year.

AngioDynamics maintains an online physician locator as part of its MVP and VIP programs, garnering thousands of referrals per month. In a recent company survey, over half of patients who sought a referral via the EVLT website saw the recommended physician and received treatment. The company also will offer physicians a range of high-quality, ready-to-use promotional material templates for optimal marketing of VenaCure EVLT to patients. More information on VenaCure EVLT and the MVP and VIP programs can be found by visiting www.VenaCureEVLT.com.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation and irreversible electroporation resection systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company's expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of the Company to integrate the purchased Diomed businesses as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2008. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.